Inflammatory linear verrucous epidermal naevus (ILVEN)

LAST UPDATED: Aug 08, 2021

Introduction

An inflammatory linear verrucous epidermal naevus (ILVEN) is an inflamed and itchy variant of an epidermal naevus. 

This chapter is set out as follows:  


History

  • Age - 75% of lesions arise during the first five years of life, most often in the first six months
  • Can be very itchy

Clinical findings

Distribution

  • Most commonly a single lesion that arises along Blaschko's lines, especially on the legs - refer to the related chapter 
  • Occasionally bilateral and more extensive 

Morphology

  • Linear and of variable length 
  • Eczematous or psoriasiform papules

Differential diagnosis

  • Lichen striatus can be distinguished by the following:
    • Rapid development
    • Age - most present over the age of one year, although some develop in infancy
    • Lack of itch
    • Spontaneous evolution, within 3-6 months for the majority 

Clinical Images

Please refer to notes on image rights at bottom of the page with regards to individual image ownership.


Management

  • Many treatments have been tried but results are often disappointing:
    • Potent topical steroids and intralesional steroids may give temporary relief
    • Cryotherapy has been used for smaller lesions
    • Laser can give a temporary clearance 
  • Unlike with lichen striatus, spontaneous resolution is uncommon

Disclaimer - the author PCDS cannot accept responsibility for any misleading or incorrect statements, and the management of individual patients remains the direct responsibility of the individual doctor. We do however hope that visitors to this site can contact us regarding comments that are considered misleading or incorrect so that we can continue to improve the site.

Image Rights - The PCDS would like to thank Dermatoweb, DermQuest (Galderma), and others who have contributed images. All named individuals and organisations maintain copyright for the relevant images.

Quick Links

The following pharmaceutical companies have had no involvement in the content of this website or in our conference programmes

Almirall
Galderma
Glenmark
Johnson & Johnson
La Roche-Posay
LEO Pharma
Pierre Fabre
Schuco